Form 4: Ocuphire Pharma CEO George Magrath Acquires 5,000 Shares
SEC Form 4
Ocuphire Pharma's CEO, George Magrath, purchased 5,000 shares of common stock at an average price of $1.7545 on May 17, 2024.
Summary
- On May 17, 2024, George Magrath, the CEO of Ocuphire Pharma, Inc., acquired 5,000 shares of common stock.
- The purchase price averaged $1.7545 per share.
- Following the transaction, Magrath directly owns 430,000 shares of Ocuphire Pharma.
- The shares were purchased in multiple transactions at prices ranging from $1.73 to $1.78, inclusive.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive signal, but the document itself is simply a regulatory filing.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's management believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date of the stock purchase transaction. |
| 05/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.